Current Research in Translational Medicine

Scope & Guideline

Bridging Laboratory Discoveries with Clinical Excellence

Introduction

Welcome to your portal for understanding Current Research in Translational Medicine, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2452-3186
PublisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 2016 to 2024
AbbreviationCURR RES TRANSL MED / Curr. Res. Transl. Med.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE

Aims and Scopes

Current Research in Translational Medicine focuses on bridging the gap between laboratory research and clinical applications, with a strong emphasis on hematological malignancies and innovative therapies. The journal aims to publish high-quality research that contributes to the understanding and management of various medical conditions, particularly through translational approaches.
  1. Hematological Malignancies:
    The journal consistently publishes research related to hematological cancers, including acute myeloid leukemia, lymphoma, and multiple myeloma, focusing on novel treatments and therapeutic strategies.
  2. Translational Research:
    A core aim is to translate laboratory findings into clinical applications, emphasizing studies that bridge experimental and clinical medicine.
  3. Cell and Gene Therapy:
    Research on cell-based therapies, particularly CAR-T cell therapy and stem cell transplantation, is a significant focus, highlighting advancements in treatment methodologies.
  4. Immunotherapy:
    The journal covers emerging immunotherapeutic strategies, investigating their efficacy and safety in treating various malignancies.
  5. Biomarkers and Diagnostics:
    There is a strong emphasis on identifying biomarkers for disease prognosis and treatment response, contributing to personalized medicine.
  6. Regenerative Medicine:
    Research involving stem cells and regenerative therapies is prevalent, showcasing innovative approaches to repair and regenerate damaged tissues.
  7. Clinical Guidelines and Best Practices:
    The journal also addresses clinical practices through guidelines and recommendations for managing hematological disorders.
Current Research in Translational Medicine is witnessing a surge in certain emerging themes that reflect the evolving landscape of medical research. This section outlines these trending areas, which are gaining prominence in recent publications.
  1. CAR-T Cell and Novel Immunotherapies:
    The increasing focus on CAR-T cell therapy and other immunotherapeutic approaches highlights the journal's commitment to cutting-edge treatments and their applications in hematological malignancies.
  2. Next-Generation Sequencing and Genomics:
    There is a growing trend towards incorporating genomic technologies such as next-generation sequencing, which aids in understanding the genetic underpinnings of diseases and personalizing treatment.
  3. Biomarker Discovery and Application:
    Research aimed at discovering and validating biomarkers for various hematological conditions is on the rise, enhancing the capabilities of precision medicine.
  4. Artificial Intelligence and Data Analytics:
    The integration of AI and data analytics in predicting treatment outcomes and patient responses is emerging as a significant trend, reflecting the journal's adaptation to technological advancements.
  5. Regenerative and Stem Cell Therapies:
    An increasing number of studies are exploring the potential of regenerative medicine and stem cell therapies, indicating a shift towards innovative approaches in treatment.
  6. Clinical Guidelines and Evidence-Based Practices:
    There is a noticeable trend towards publishing clinical guidelines and recommendations, aiming to standardize practices and improve patient care in hematological oncology.

Declining or Waning

While Current Research in Translational Medicine maintains a robust focus on hematological disorders and innovative therapies, certain themes have shown signs of decline in recent publications. This section highlights these waning areas.
  1. Solid Tumor Research:
    Research specifically focused on solid tumors has decreased, indicating a shift towards hematological malignancies and therapies related to blood cancers.
  2. Traditional Pharmacotherapy:
    There appears to be a reduction in studies centered on conventional pharmacological treatments, as innovative therapies like immunotherapy and gene therapy become more prominent.
  3. Infectious Disease Research:
    While COVID-19 research was significant during the pandemic, the volume of papers addressing infectious diseases outside the context of hematological malignancies has lessened.
  4. Basic Science Studies:
    There is a noticeable decline in purely basic science research that does not directly translate to clinical applications, as the journal increasingly emphasizes translational studies.

Similar Journals

Organogenesis

Unveiling the Complexities of Organogenesis.
Publisher: TAYLOR & FRANCIS INCISSN: 1547-6278Frequency: 4 issues/year

Organogenesis is a leading journal published by Taylor & Francis Inc, dedicated to advancing the field of developmental biology and regenerative medicine. With an ISSN of 1547-6278 and E-ISSN 1555-8592, this journal spans an extensive research scope that includes embryology, transplantation, and biomedical engineering, distinguishing itself as a crucial platform for researchers and practitioners alike. Its impact is reflected in its performance across various categories in 2023, earning Q3 rankings in Biomedical Engineering and Embryology, Q4 in Developmental Biology, and Q2 in Transplantation, showcasing its reputable standing among peer journals. Moreover, with Scopus rankings indicating strong positioning in the fields of medicine and biochemistry, Organogenesis is essential for those looking to publish or stay updated on pioneering research. The journal facilitates rigorous peer-review and offers a forum for disseminating innovative findings, making it an invaluable resource for academics, professionals, and students committed to understanding the complexities of organism development.

Hematology Transfusion and Cell Therapy

Fostering collaboration for groundbreaking blood health solutions.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Exploring Innovative Therapies for Cancer Patients
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

HEMATOLOGICAL ONCOLOGY

Shaping the Future of Cancer Treatment and Research
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Egyptian Journal of Haematology

Advancing Hematology: Insights from Egypt and Beyond
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

npj Regenerative Medicine

Transforming Science into Healing Solutions.
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Regenerative Medicine, published by NATURE PORTFOLIO, is at the forefront of research and innovation in the field of regenerative medicine, fostering a deep understanding of cellular and molecular processes that can be leveraged for therapeutic advancements. Launched as an Open Access journal since 2016, it ensures wide dissemination of knowledge, allowing researchers, professionals, and students to access high-quality articles without barriers. With an impressive impact, it holds Q1 ratings across multiple categories including Biomedical Engineering, Cell Biology, Developmental Biology, and Medicine (miscellaneous) as of 2023, indicating its critical role in shaping contemporary scientific discourse. The journal ranks notably within the top 10% in multiple Scopus categories, indicating its commitment to publishing pioneering research that addresses pressing challenges in regenerative therapies. Addressing the dynamic convergence of disciplines, npj Regenerative Medicine is poised to not only impact academic thought but also translate into clinical applications, making it a pivotal resource for those invested in the future of medicine.

Current Medical Science

Advancing the Frontiers of Medical Knowledge
Publisher: SPRINGERISSN: 2096-5230Frequency: 6 issues/year

Current Medical Science is a prominent academic journal dedicated to advancing knowledge in the fields of Medicine, Biochemistry, and Genetics. Published by SPRINGER with an ISSN of 2096-5230 and E-ISSN 2523-899X, this journal is based in China and serves as a vital resource for researchers, professionals, and students alike. With a focus on innovative research and emerging trends, Current Medical Science has established itself with an impactful presence, operating under Open Access guidelines to ensure wide dissemination of scientific findings. The journal's recognition is underscored by its impressive Scopus rankings, including a Q3 quartile placement in Biochemistry and Genetics as of 2023. It is noteworthy that the journal spans converged years from 2018 to 2024, providing a comprehensive platform for scholarly discussions and developments that drive the evolution of medical science. As it continues to publish influential research, Current Medical Science plays an essential role in bridging the gap between laboratory science and clinical application.

Journal of Stem Cells & Regenerative Medicine

Innovating Tomorrow's Regenerative Solutions
Publisher: JOURNAL STEM CELLS & REGENERATIVE MEDICINEISSN: 0973-7154Frequency: 2 issues/year

The Journal of Stem Cells & Regenerative Medicine is a leading publication dedicated to the advancing field of stem cell research and regenerative medicine. Established in India and published by JOURNAL STEM CELLS & REGENERATIVE MEDICINE, this Open Access journal has been available since 2007, providing researchers and practitioners with free and unrestricted access to high-quality articles. With an ISSN of 0973-7154, the journal is indexed in Scopus, featuring a wide array of topics and insights into biochemistry, biotechnology, cell biology, and molecular biology, as denoted by its relevant quartile rankings. This journal is committed to bridging the gap between laboratory research and clinical applications, making significant contributions to the scientific community. The convergence of innovative studies from 2010 to 2024 positions it as an invaluable resource for those looking to stay at the forefront of stem cell and regenerative medicine research.

CURRENT MOLECULAR MEDICINE

Connecting Science to Medicine for a Healthier Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1566-5240Frequency: 10 issues/year

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

Transfusionsmedizin

Innovating blood transfusion practices through research.
Publisher: GEORG THIEME VERLAG KGISSN: 2191-8805Frequency: 4 issues/year

Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.